Evidence map›Paper›PMID 22315270›Full record

GuidelineChest2012

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Lori-Ann Linkins, Antonio L Dans, Lisa K Moores, Robert Bona, Bruce L Davidson, Sam Schulman, Mark Crowther

Erratum issued Registry-linked trialOpen access · bronzeAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03148912 (Optimizing the Diagnosis of Heparin Induced Thrombocytopenia Using Quantified Anti-Platelet Factor 4 Immunological Testing), which is not on this map. Cited by 288 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
288citing papers in PubMed, 8 pooled it
99.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03148912 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Optimizing the Diagnosis of Heparin Induced Thrombocytopenia Using Quantified Anti-Platelet Factor 4 Immunological Testing: A Pilot Multicentre Cohort Study

TypeinterventionalSponsorOttawa Hospital Research InstituteRan2018 to 2022Enrolled180ConditionsHeparin-induced Thrombocytopenia (HIT)ArmsDiagnostic algorithm
3 · Its place in the literature

Who cites it

288 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,002 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pentasaccharides for the treatment of deep vein thrombosis.The Cochrane database of systematic reviews · 2017
    Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Clinical Significance of the Serotonin Release Assay and Platelet Count Monitoring After Cardiac Surgery.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018
    Trial
  12. Trial
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

228 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Lori-Ann LinkinsDepartment of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: linkinla@mcmaster.ca.
Antonio L DansCollege of Medicine, University of the Philippines Manila, Manila, Philippines.
Lisa K MooresThe Uniformed Services, University of Health Sciences, Bethesda, MD.
Robert BonaSchool of Medicine, Quinnipiac University, North Haven, CT.
Bruce L DavidsonUniversity of Washington School of Medicine, Seattle, WA.
Sam SchulmanDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Mark CrowtherDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
McMaster University · CAQuinnipiac University · USUniversity of Health SciencesUniversity of the Philippines Manila · PHUniversity of Washington · US

Funding

Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based ClinicalR13HL104758 · NHLBI · AMERICAN COLLEGE OF CHEST PHYSICIANS · PI LEWIS, SANDRA ZELMAN · 2010 to 2010
$11k
NHLBI NIH HHS R13 HL104758
6 · The paper itself

Abstract

backgroundHeparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that can lead to devastating thromboembolic complications, including pulmonary embolism, ischemic limb necrosis necessitating limb amputation, acute myocardial infarction, and stroke.

methodsThe methods of this guideline follow the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement.

resultsAmong the key recommendations for this article are the following: For patients receiving heparin in whom clinicians consider the risk of HIT to be > 1%, we suggest that platelet count monitoring be performed every 2 or 3 days from day 4 to day 14 (or until heparin is stopped, whichever occurs first) (Grade 2C). For patients receiving heparin in whom clinicians consider the risk of HIT to be < 1%, we suggest that platelet counts not be monitored (Grade 2C). In patients with HIT with thrombosis (HITT) or isolated HIT who have normal renal function, we suggest the use of argatroban or lepirudin or danaparoid over other nonheparin anticoagulants (Grade 2C). In patients with HITT and renal insufficiency, we suggest the use of argatroban over other nonheparin anticoagulants (Grade 2C). In patients with acute HIT or subacute HIT who require urgent cardiac surgery, we suggest the use of bivalirudin over other nonheparin anticoagulants or heparin plus antiplatelet agents (Grade 2C).

conclusionsFurther studies evaluating the role of fondaparinux and the new oral anticoagulants in the treatment of HIT are needed.

Indexed as

Evidence-Based MedicineSocieties, MedicalAnticoagulantsDrug Therapy, CombinationFibrinolytic AgentsHeparinHumansInternational Normalized RatioPlatelet CountRisk FactorsThrombocytopeniaThromboembolismThrombosisUnited StatesVitamin KAnticoagulantsFibrinolytic AgentsHeparinVitamin K

Identifiers

PMID22315270
PMCPMC3278058
OpenAlexW2140436541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.